Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820233 · ClinicalTrials.gov registry record
Studies of Neuregulin/ERBB Signaling in Human Heart
A clinical trial of Heart Failure and Heart Disease, sponsored by Douglas B. Sawyer.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT02820233 is a study of Heart Failure and Heart Disease that is actively recruiting participants, run by Douglas B. Sawyer. The registered enrollment target is 80 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02820233, a study of Heart Failure and Heart Disease, is actively recruiting participants, sponsored by Douglas B. Sawyer.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Conditions Studied
Study Locations (1)
Maine
- Maine Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-06 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02820233
The ClinicalTrials.gov registry entry for NCT02820233 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The listed sponsor is Douglas B. Sawyer, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.
NCT02820233 reports 1 study location spanning 1 distinct geographic area - top geographies include Maine.
Frequently Asked Questions
What is clinical trial NCT02820233 about?
NCT02820233 is a clinical study titled "Studies of Neuregulin/ERBB Signaling in Human Heart". This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
What is the current status of trial NCT02820233?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2015-06. Estimated completion is 2029-06.
What conditions does trial NCT02820233 study?
This clinical trial studies the following conditions: Heart Failure, Heart Disease, Vascular Disease.
Who is sponsoring clinical trial NCT02820233?
This trial is sponsored by Douglas B. Sawyer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02820233 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.